Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

The therapy failed to slow disease progression in patients with early Alzheimer’s in the INVOKE-2 trial (NCT04592874).

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

Don't Miss our Black Friday Offers: Graig Suvannavejh’s rating is based on several strategic considerations despite the recent disappointing data for Alector’s AL002. Although the Phase 2 results for ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

The drug, called AL002, is designed to activate a group of surveilling neuronal immune cells called microglia. It was among ...

He stated that the funds would support the company's transformational data expectations from their upcoming clinical trials, including the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRONT ...